Gilead Sciences

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Jan 31, 2026

Business

Edwards Lifesciences Halts JenaValve Acquisition, Doubles Down on Core Valve Technology

Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.

Feb 2, 2026

Business

Edwards Lifesciences: Strong Fundamentals Mask Growth Concerns as Stock Slips

Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Feb 2, 2026

Business

IDEAYA Biosciences: A Buying Opportunity After the Pullback, or Priced for Perfection?

IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.

Feb 2, 2026

Business

Edwards Lifesciences Gains Analyst Favor as Renewed Growth Cycle Takes Hold

Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.

Jan 30, 2026

Business

Eli Lilly Commits $3.5 Billion to Pennsylvania, Creating 850 Jobs in Major Life Sciences Push

Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.

Jan 30, 2026

Business

Harmony CFO's Complete Stock Sale Raises Eyebrows Amid Upbeat Revenue Forecasts

Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.

Feb 2, 2026

Business

Guggenheim Boosts Bruker Price Target to $58, Citing Strong Diagnostics Outlook

Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.

Jan 30, 2026

Business

Three TSX Venture Penny Stocks Poised for Growth Amid Canada's Steady Rate Environment

As the Bank of Canada signals a hold on interest rates, a backdrop of market stability is emerging. This analysis delves into three Canadian penny stocks—Britannia Life Sciences, ROK Resources, and Vision Lithium—that present distinct risk-reward profiles for investors eyeing the junior markets in early 2026.

Jan 30, 2026

Business

Qiagen's Stock in Focus: Is the Recent Rally Sustainable Amid Valuation Debate?

Shares of life sciences toolmaker Qiagen (NYSE:QGEN) have shown renewed momentum, gaining over 12% in the past month. This surge brings the company's valuation into sharp focus, with analysts divided between near-term earnings multiples and long-term cash flow projections.

Jan 30, 2026

Business

Thermo Fisher Scientific Caps 'Strong Year' with Robust Q4, Eyes Strategic Growth Amid Market Headwinds

Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.

Jan 30, 2026

Business

China Approves Sciwind's Diabetes Drug Xianyida, Intensifying GLP-1 Market Competition

Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.

Jan 30, 2026

Business

BD Strikes Waters Deal and Advances Medical Plastics Recycling in Strategic Overhaul

Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.

Jan 30, 2026

Business

Veeva Systems: A Buying Opportunity or Overvalued Tech Play? Analysts Weigh In

Veeva Systems' stock has faced recent pressure, declining over 11% in the past year. A deep dive into its valuation reveals a stark contrast: a discounted cash flow model suggests significant upside, while its premium P/E ratio tells a more cautious tale. We examine the numbers and what they mean for investors eyeing the life sciences cloud leader.

Jan 30, 2026

Business

Siemens Healthineers Bets on Irish Innovation with New €10 Million R&D Hub

The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.

Feb 2, 2026

Business

Danaher Forges Strategic Alliance with Automata, Accelerating AI-Powered Laboratory Automation

Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.

Jan 31, 2026

Business

Cash Flow Caution: Three High-Yield Stocks Facing Headwinds

Robust cash generation is a hallmark of financial health, but it doesn't guarantee future performance. We examine three companies with strong free cash flow margins whose underlying challenges—from competitive pressures to growth concerns—suggest investors should look closer before buying.

Jan 30, 2026

Business

Twist Bioscience Powers Ahead: Q1 2026 Revenue Jumps 17%, Fueled by AI-Driven Discovery Boom

Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.

Feb 2, 2026